Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Implants / Devices
    • MicroPort Scientific...

    MicroPort Scientific India plans expansion of product portfolio

    Written by Ruby Khatun Khatun Published On 2017-07-20T14:28:46+05:30  |  Updated On 20 July 2017 2:28 PM IST
    MicroPort Scientific India plans expansion of product portfolio

    Mumbai: MicroPort Scientific India, an Indian arm of Shanghai-based medical device firm MicroPort Scientific Corporation on Wednesday said it is looking at expanding horizontally and vertically in terms of expansion across the country as well as product portfolios.


    "We will be expanding horizontally and vertically in terms of expansion across the country as well as product portfolios.


    "Our global leadership has very robust expansion plans for India. We have a firm commitment from the management to infuse investment required to achieve our fast sustainable growth," MicroPort Scientific India managing director Riyaz Desai said in a statement here.


    The company provides medical solutions covering 10 major disciplines including interventional cardiology, orthopedics, endovascular, neurovascular, electrophysiology, diabetes and endocrine management, surgical management and others, it said.


    The company has innovative TES (Target Eluting Stent) technology product FireHawk and it is eyeing at about 20 per cent market share in the stent business. Our TES suggest the healing time is lesser than other Drug Eluting Stents (DES), he said.


    Commenting on the recent price regulation of cardio vascular stents by NPPA, Desai said, the company is completely aligned with government's mission of providing affordable healthcare.


    "While many companies are being compelled by the government to offer their latest technologies, we are voluntarily going to the market and offering our best in class technology at the regulated pricing.


    "This will have profound impact as more doctors and patients will opt for this technology and certainly can have better long term clinical outcomes.


    "We have other product portfolios in various therapeutic areas like orthopedic, neurovascular, peripheral vascular and electrophysiology and will be launched in the country soon," Desai said.


    The company's short term investment would be in people and education. In long term it is also exploring opportunities to have local manufacturing and partners with the government in 'Make in India' initiatives, he added.


    MicroPort Scientific Corporation is a leading medical device company with business focussing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally and its products currently approved for use in over 5,000 hospitals in 80 countries worldwide.


    Under its global expansion programme, Microport has acquired OrthoRecon business of Wright Medical, USA and has made a strategic investment in Lombard Medical of UK.

    diabetesDrug Eluting StentsExpansioninterventional cardiologyMedical DevicesMicroPortMicroPort Scientific IndiaorthopedicsOrthoReconplanproduct portfolioRiyaz DesaiTarget Eluting Stent
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok